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Epigenetics is defined as heritable changes that affect gene expression without 
altering the DNA sequence. Epigenetic regulation of gene expression is 
facilitated through different mechanisms such as DNA methylation, histone 
modifications and RNA-associated silencing by small non-coding RNAs. All 
these mechanisms are crucial for normal development, differentiation and 
tissue-specific gene expression. These three systems interact and stabilize one 
another and can initiate and sustain epigenetic silencing, thus determining 
heritable changes in gene expression. Histone acetylation regulates diverse 
cellular functions including inflammatory gene expression, DNA repair and cell 
proliferation. Transcriptional coactivators possess intrinsic histone 
acetyltransferase activity and this activity drives inflammatory gene expression. 
Eleven classical histone deacetylases (HDACs) act to regulate the expression of 
distinct subsets of inflammatory/immune genes. Thus, loss of HDAC activity 
or the presence of HDAC inhibitors can further enhance inflammatory gene 
expression by producing a gene-specific change in HAT activity. For example, 
HDAC2 expression and activity are reduced in lung macrophages, biopsy 
specimens, and blood cells from patients with severe asthma and smoking 
asthmatics, as well as in patients with chronic obstructive pulmonary disease 
(COPD).  This may account, at least in part, for the enhanced inflammation and 
reduced steroid responsiveness seen in these patients. Other proteins, 
particularly transcription factors, are also acetylated and are targets for 
deacetylation by HDACs and sirtuins, a related family of 7 predominantly 
protein deacetylases.  Thus the acetylation/deacetylation status of NF-κB and 
the glucocorticoid receptor can also affect the overall expression pattern of 
inflammatory genes and regulate the inflammatory response. Understanding 
and targeting specific enzymes involved in this process might lead to new 
therapeutic agents, particularly in situations in which current anti-
inflammatory therapies are suboptimal. 
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INTRODUCTION 
Many lung diseases, including asthma, chronic 
obstructive pulmonary disease (COPD), cystic fibrosis, 
interstitial lung disease and acute respiratory distress 
syndrome, involve inflammation, with the coordinate 
expression of multiple inflammatory genes in the lungs. 
These inflammatory genes code for the expression of 
cytokines, chemokines, enzymes that synthesize 
inflammatory mediators, inflammatory mediator receptors 
and adhesion molecules, resulting in a regulated influx and 
activation of inflammatory cells and stimulation of resident 
structural cells. Many of these inflammatory genes are 
regulated by proinflammatory transcription factors, 
including nuclear factor kappaB (NF-κB) and activator 
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protein (AP)-1. These transcription factors orchestrate, 
amplify and perpetuate the inflammatory response and 
form the molecular basis of chronic inflammation (1-3). The 
term epigenetics; as currently used, refers to a change in 
gene expression which is heritable but that does not 
involve any change in DNA sequence.  
Post-translational modifications of histones play an 
important role in epigenetic regulation of gene expression, 
and thus have critical effects on environment-mediated 
chronic lung diseases such as COPD and asthma (4,5). 
Since histones are post-translationally modified during 
disease progression, the identification of these patterns as 
well as the altered activity of the enzymes that ‘write’ and 
‘erase’ these marks are important mechanisms for the 
understanding of human diseases. The most intensively 
studied modifications are histone acetylation and 
methylation which through the action of specific enzymes 
form marks that allow ‘readers’ of these marks to remodel 
chromatin producing the open chromatin structure 
associated with active gene transcription or a closed 
repressive chromatin state linked to a lack of active 
transcription (6). For example, an acetylated lysine residue 
forms a bromodomain that is read by many enzymes and 
transcription regulating factors (7)(Fig. 1). 
 
 
 
 
 
 
 
Figure 1. Histone acetyltransferases (HATs) acetylate (AC) histones on lysine 
residues to leave a bromodomain (acetylated lysine) residue as an epigenetic 
mark.  This is read by a bromodomain containing protein such as those found in 
a chromatin remodeling enzymes which can then alter chromatin structure and 
allow gene transcription to occur.  Acetylated tags are removed by erasers such 
as histone deacetylases (HDACs). 
 
Abnormalities in histone acetylation and methylation 
resulting from an imbalance in histone acetylation 
(HAT)/histone deacetylase (HDAC) and histone 
methyltransferase (HMT)/histone demethylase (HDM) 
activities are associated with a change in gene expression 
(Fig. 2) (8-10).  However, global abnormalities linking 
epigenetics to airways disease are only just being 
investigated.  
Oxidative stress has been implicated in the 
pathogenesis of several inflammatory lung disorders 
including COPD due to its effect on pro-inflammatory 
gene transcription. In this regard it has been shown that 
NF-κB-dependent gene expression, at least in part, is 
regulated by gene-specific changes in the acetylation and 
methylation status of selective histone H3 and H4 residues 
(11).  
Cigarette smoke (CS) and oxidants alter the activity of 
both HATs and HDACs and thereby enhance NF-κB-
dependent gene expression (12). Furthermore, prolonged 
exposure of human airway epithelial cells to CS in vitro 
results in marked temporal changes in histone acetylation 
and methylation patterns, altered DNA methylation and 
modifies the cell phenotype (13).  
CS/oxidants also reduce glucocorticoid sensitivity by 
attenuating HDAC2 activity and expression and this has 
been proposed to account, at least in part, for the relative 
glucocorticoid insensitivity seen in patients with COPD 
(14). Understanding the mechanisms of NF-κB regulation 
and the balance between histone acetylation and 
deacetylation may lead to the development of novel 
therapies in lung inflammation and injury.  Importantly, 
bromodomain mimics such as JQ1 and I-BET have been 
shown to switch off specific sets of inflammatory genes in 
human macrophages and to completely suppress sepsis 
and cancer in murine models of disease and more recently 
to prevent multiple myeloma (15-17). 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic cartoon indicating how the balance between the gene 
transcription and gene repression is controlled by alterations in histone 
acetylation status. 
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The aim of this review is to highlight the immune-
inflammatory responses linked to epigenetic chromatin 
alterations in lungs disease, and the importance and role of 
histone acetylation in modulating chronic lung diseases 
augmented by exposure to cigarette smoke and 
environmental agents such as airborne particulates and 
allergens.  HMT regulation of inflammatory gene 
expression is more complex as the effect on gene 
transcription is dependent upon the specific methylated 
residue and the degree of methylation on each residue e.g. 
mono-, di- and tri-methylated lysine.  As a result this will 
not be discussed here but the reader is directed to an 
excellent review (18). The role of small non-coding RNAs 
in the epigenetic control of inflammation is becoming 
increasingly apparent such as the differential expression of 
miR38-5p and miR146 in severe asthma (19). A review of 
the roles of miRNAs in airways disease is not discussed 
here but is discussed elsewhere (20, 21).  
 
Chromatin modification and inflammatory gene 
expression 
Gene expression in all tissues including the lung is 
regulated, at least in part, through coordinated changes in 
the pattern of histone post translational modifications (22-
26). The specific role of histone acetylation via the actions 
of histone acetylases (HAT) and histone deacetylases 
(HDAC) has been extensively described (22-26). In a 
simplistic form increased histone acetylation is associated 
with increased inflammatory gene expression.  Increased 
HAT activity and decreased HDAC activity have been 
reported in asthma along with reduced HDAC activity in 
COPD.  In both cases this is linked to the altered 
inflammatory response seen in these diseases (27). For 
example, there is increased acetylation of histone-4 in 
asthma, consistent with increased expression of multiple 
inflammatory genes (28). In peripheral lung, airway 
biopsies and alveolar macrophages from COPD patients 
there is increased acetylation of histones within 
inflammatory gene promoter regions such as that of 
CXCL8/IL-8 (29). CXCL8 is regulated by NF-κB and the 
degree of CXCL8 promoter acetylation correlates CXCL8 
mRNA and with disease severity (30). 
 
Histone deacetylases (HDAC) and histone acetylases 
(HAT) 
Eukaryotic DNA is highly organized and packaged into 
the nucleus. The organization and packaging are achieved 
through the addition of proteins, including two of each 
core histones H2A, H2B, H3 and H4 which, together with 
DNA, form the nucleosome structure (31).  HAT enzymes, 
now known as writers of epigenetic marks, acetylate the ε-
amino groups of lysine residues located near the amino 
termini of core histone proteins.  These acetyl marks 
(bromodomains) are detected by epigenetic readers which 
are found in transcription factors, transcriptional co-factors 
and chromatin remodeling enzyme complexes.  These later 
complexes alter the local chromatin structure by allowing 
nucleosomal movement in an ATP-dependent manner and 
recruitment of the basal transcriptional machinery (32). 
Thus, the level of acetylation is related to transcriptional 
activity due to the formation of an open chromatin 
confirmation (31). Histone acetylation must be reversed to 
prevent uncontrolled gene expression.  This is performed 
by histone deacetylases (HDACs) which are therefore 
associated with gene silencing (6)(Fig. 1).  It is important to 
note that HDACs are also involved in the reversible 
acetylation of non-histone proteins including transcription 
factors such as NF-κB (33) and the glucocorticoid receptor 
(6) and inflammatory enzymes such as p38 MAPK adding 
another layer of control to cellular function by 
HAT/HDAC activity (Fig. 3)(34, 35). 
 
 
 
 
 
 
 
Figure 3. The regulation of the acetylation status of histone and non-histone 
proteins is essential for a wide variety of cell functions. 
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For example, steroid resistance has been linked to 
changes in p38 MAPK activity and recent evidence 
indicates that acetylation of this enzyme results in a greater 
activation than phosphorylation providing a link between 
these two processes underlying steroid responsiveness 
(35). 
Thus, expression of inflammatory genes is determined 
by a balance between histone acetylation (which activates 
transcription) and deacetylation, which switches off 
transcription. There are 11 HDAC isoenzymes that 
deacetylate histones within the nucleus, and specific 
HDACs appear to be differentially regulated and to 
regulate different groups of genes (36)(Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. HATs and HDACs exist in distinct families. 
 
Mammalian HDACs have been classified into three 
classes. Class I (HDACs 1, 2, 3 & 8; each of which contains 
a deacetylase domain exhibiting from 45% to 93% identity 
in amino acid sequence) are homologs of yeast RPD3 and 
are localized to the nucleus (37,  38).  Class II (HDACs 4, 5, 
6, 7, 9 & 10) are homologs of yeast Hda1 and are found in 
both the nucleus and cytoplasm. The molecular weights of 
which are all about twofold larger than those of the class I 
members, and the deacetylase domains are present within 
the C-terminal regions, except that HDAC-6 contains two 
copies of the domain, one within each of the N-terminal 
and C-terminal regions (39).  HDAC11 has properties of 
both class I and class II HDACs. Class III (Sirt1 - Sirt7) are 
homologs of yeast Sir2 and form a structurally distinct 
class of NAD-dependent enzymes found in both the 
nucleus and cytoplasm. Histone acetylation not only 
regulates inflammatory gene expression but plays a role in 
diverse functions such as DNA repair and cell proliferation 
and apoptosis (40, 41) and are therefore implicated in 
many types of cancer (42, 43)(Fig. 3). However, the actions 
of HDAC inhibitors used in cancer therapy probably 
relates to their effects on non-histone proteins (44).  
 
Role and function of epigenetic modifications in 
pathogenesis of lung diseases 
A) Lung cancer: Changes in DNA methylation are also 
described in lung cancer (45). The CpG dinucleotide, which 
is usually underrepresented in the genome, is clustered in 
the promoter regions of some genes. These promoter 
regions have been termed CpG islands (45). CpG islands 
are protected from methylation in normal cells, with the 
exception of genes on the inactive X chromosome and 
imprinted genes. This protection is critical, since the 
methylation of promoter region CpG islands is associated 
with a loss of expression of these genes. The following 
three different alterations in DNA methylation are 
common in human cancer: (1) global hypomethylation, 
often seen within the body of genes; (2) dysregulation of 
DNA methyltransferase I, the enzyme involved in 
maintaining methylation patterns, and potentially other 
methyltransferases; and (3) regional hypermethylation in 
normally unmethylated CpG islands particularly those 
associated with tumor suppressor genes. 
As indicated earlier, gene expression is regulated by a 
dynamic balance between HAT and HDAC activities and 
changes in histone acetylation patterns have been reported 
in many human diseases, particularly cancer (46) and 
investigators have used HDAC inhibitors against many 
malignancies (47). HDAC inhibitors induce apoptotic cell 
death in a number of tumor cell types (40, 41), probably 
through targeting non-histone proteins, whereas normal 
cells are usually resistant to cell death caused by HDAC 
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inhibitors (48-50).  The discovery of bromodomain (Brd) 
mimics has enabled more selective suppression of this 
HAT/HDAC/gene expression nexus and a Brd4 mimic 
has recently been reported to be effective in multiple 
myeloma (50, 51). 
B) Asthma:  Post-translational modifications of histones 
play a key role in epigenetic regulation of gene expression 
and may therefore play an important role in environment-
mediated chronic lung diseases like asthma (9,10). Asthma 
is a chronic inflammatory disease of the airways 
characterized by reduced airway patency, which is 
regulated by bronchodilators such as β-agonists, and by 
the infiltration of inflammatory and immune cells, which is 
treated by corticosteroids (52). Asthma phenotypes are 
highly heritable and the subject of many genetic 
researches. The occurrence of patients with an asthma 
cluster in their family indicates that a genetic component is 
likely operating. Twin studies represent a useful first step 
to determine whether a given trait or disease has a 
measurable genetic component. In a large twin study with 
7,000 same-sex twins born between 1886 and 1925, the 
concordance rate for self-reported asthma in monozygotic 
twin pairs was 19%, which is four times higher than the 
4.8% rate in dizygotic twins (53).   
Since this does not fully account for the heritability of 
asthma other mechanisms including epigenetics have been 
implicated in the pathogenesis of asthma (52). In bronchial 
biopsies from patients with asthma, there is a marked 
increase in HAT activity and a small reduction in HDAC 
activity compared with normal airways, thus favoring 
increased inflammatory gene expression (26). Interestingly, 
in patients with asthma who smoke, there is a significantly 
greater reduction of HDAC activity in bronchial biopsies 
than in nonsmoking asthmatic patients (26) and this may 
account for why these smoking asthmatics have more 
severe asthma and resistance to steroids (54).  
C) COPD: Pulmonary inflammation including 
infiltration of neutrophils and macrophages plays a central 
role in the etiology of COPD as evidenced in the 
emphysematous lungs of smokers and in mice exposed to 
cigarette smoke (55).  Pulmonary inflammation in COPD is 
associated with fibrosis and irreversible narrowing of small 
airways and destruction of the lung parenchyma or 
emphysema (56).  It is generally accepted that genetic 
predisposition plays a role in COPD development in 
susceptible individuals.  Many candidate genes that could 
be linked to the development of disease have been 
examined in COPD and more recent GWAS analysis has 
been performed (57).  
However, inconsistent results in different study 
populations have limited this approach and suggest that 
other factors such as epigenetics may be important in 
understanding the gene-environment aspects involved in 
the susceptibility to COPD in smokers.  
In COPD patients’ peripheral lung and airway biopsy 
specimens, and alveolar macrophages, there is an increase 
in the acetylation of histones associated with the promoter 
region of inflammatory genes, such as CXCL8, that are 
regulated by NF-κB and the degree of acetylation increases 
with disease severity (27).  
This increased acetylation of inflammatory genes is not 
due to any global increase in histone acetyltransferase 
activity in the lungs or macrophages but a reduction in 
HDAC activity in alveolar macrophages of cigarette 
smokers compared to nonsmokers, and this is correlated 
with increased expression of inflammatory genes in these 
cells (58, 59). There is also a reduction in total HDAC 
activity in peripheral lung, bronchial biopsy specimens and 
alveolar macrophages from COPD patients and this is 
correlated with disease severity and with increased gene 
expression of CXCL8 (27). 
There is a selective reduction in the expression of 
HDAC-2, with lesser reductions in HDAC-3, -5 and -8 and 
an increase in HDAC-4 and -6 (27).  
In patients with very severe COPD (Global Initiative for 
Chronic Obstructive Lung Disease stage 4) the expression 
of HDAC-2 was < 5% of that seen in normal lung. The 
reasons for the reduction in HDAC, particularly HDAC-2, 
in COPD are not yet completely understood. However, 
there is increasing evidence that this may be due to 
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inactivation of the enzyme due to the presence of oxidative 
and nitrative stress (60, 61).  HDAC-2 shows increased 
tyrosine nitration in macrophages and peripheral lung 
specimens of COPD patients and this is correlated with 
increased expression of CXCL8 (62). HAT activity is 
increased and HDAC2 activity is reduced in lungs of rats 
exposed to cigarette smoke, which show increased NF-κB 
activation and expression of inflammatory genes (63).  
In addition, alveolar macrophages from normal 
smokers also show a reduction in HDAC activity and 
expression of HDAC2, and this is correlated with an 
increase in release of TNF-α and CXCL8 in response to an 
inflammatory stimulus (58) and a failure to respond to the 
presence of exogenous dexamethasone. 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a 
transcription factor that is activated in response to 
oxidative stress and as a result switches on the expression 
of anti-inflammatory genes such as haemoxygenase (HO)-1  
(64).  Down-regulation of Nrf2 expression in COPD (64,65) 
may account for the enhanced oxidative stress seen in this 
disease.  Nrf2 is an acetylated protein and enhanced 
acetylation leads to reduced Nrf2 stability and an impaired 
anti-oxidant response providing a feed forward 
mechanism to enhance inflammation and reduce steroid 
responsiveness in COPD (64). 
Epigenetic mechanisms can affect the transcriptional 
activity of specific genes, at different points in time and in 
different organs. Therefore, unlike genetic analysis that can 
use blood cells the analysis of epigenetic profiles in 
airways disease must be performed in samples obtained 
from the airways of subjects with disease.  Mapping and 
understanding global epigenetic changes in cell and tissue 
samples from bronchial biopsies, brushings and alveolar 
macrophages in stable disease and potentially in 
exacerbations is now an active area of research (65-67).  In 
addition, the effect of environmental stimuli such as diesel 
particles and cigarette smoke on epigenetic profiles is 
being investigated at the cell and epidemiological levels to 
further appreciate the potential for gene-environment 
effects on airway inflammation and disease (68-71).  Of 
note, monozygotic twins who have a greater degree of pro-
inflammatory epigenetic changes as a result of 
environmental stressors for over 50 years (72,73) are more 
susceptible to chronic disease.  
Since histones are post-translationally modified during 
disease progression, the identification of these patterns is 
important for the understanding of human epigenetic 
marks in disease conditions. Although the majority of 
information currently available relates to changes in 
histone acetylation and methylation along with DNA 
methylation changes in tumor suppressor genes in lung 
cancer, it is likely that other modifications may prove to be 
important in the regulation of inflammatory gene 
expression in these diseases as more unbiased techniques 
such as proteomics are applied (6). 
 
 
 
 
 
 
 
 
 
 
Figure 5. Oxidative stress and inflammation modulate the HAT/HDAC ratio and 
thereby control cell death (emphysema), cell proliferation and inflammation along 
with alterations in steroid function.  The later process may also involve 
acetylation of p38 MAPK.  Feedback mechanisms, such as Nrf2 acetylation, also 
exist to control oxidative stress and inflammatory processes.  Drugs that modify 
the HAT/DAC ratio may be useful in modifying these cellular functions (see text 
for details). 
 
There is emerging evidence supporting a role of 
epigenetics in the regulation of inflammatory genes in 
diseases such as COPD. Moreover, recent studies suggest 
that the currently used treatments including corticosteroids 
may work through epigenetic mechanisms. Epigenetic 
regulation can be reprogrammed, potentially affecting the 
risk, etiology and treatment of various disease states. The 
epigenetically influenced phenotype could be reversed 
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with demethylating or deacetylating agents, consistent 
with epigenetic plasticity. The postnatal reversibility of 
these methylation or acetylation events may therefore 
provide good opportunities for intervention. Furthermore, 
the development of bromodomain mimics and their utility 
in models of inflammation and cancer suggest that similar 
drugs may prove useful in COPD.  The recognition of the 
role of epigenetic mechanisms in the development of 
COPD may identify novel targets that result in new 
therapies for patients with COPD (Fig. 5). 
 
CONCLUSION 
In many patients with pulmonary disease there is a 
selective reduction in the activity and/or expression of 
specific HDAC isoforms in the peripheral lung, airways 
and in alveolar macrophages.  This may worsen as the 
disease becomes more severe. For example, this may 
account for the increased pulmonary inflammation and 
resistance to corticosteroids observed in COPD and in 
severe asthma. In COPD, there is a selective reduction in 
HDAC2 expression and this may be due to oxidative and 
nitrative stress which is increased in the airways of these 
patients. Therapeutic options aimed at increasing HDAC 
activity, such as antioxidants, iNOS inhibitors and 
theophylline may be beneficial. Alternatively, 
bromodomain mimetics may prevent aberrant 
inflammatory gene expression.  Reduced HDAC activity 
may also occur in other inflammatory diseases like in 
asthmatic patients who smoke, patients with lung fibrosis 
and those with rheumatoid arthritis and inflammatory 
bowel disease. This area of research may lead to the 
development of novel anti-inflammatory therapies aimed 
at increasing modulating HAT/HDAC activity in the 
future. 
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